RGS2 determines the preventive effects of ARBs against vascular remodeling: toward personalized medicine of anti-hypertensive therapy with ARBs.

摘要

The clinical goal of anti-hypertensive therapy is not the reduction of blood pressure, but the prevention of cardiovascular diseases (CVDs). In practical terms, as blood pressure is closely associated with CVDs, anti-hypertensive medications are chosen by considering their effectiveness at reducing blood pressure; however, cynically speaking, even if some cardiovascular events occur in medicated patients, it is impossible to ascertain that the medication is inadequate for each patient because no 'control' treatment exists in the individual case. Therefore, personalized medicine is expected to improve the outcome of hypertension treatment. To that end, much effort has been made to establish predictive biomarkers for drug response to prevent CVDs.